Home > Newsletters > FDAnews Drug Daily Bulletin > ANDA Filers Fret: Stability Testing Tweaks Will Delay Approvals
FDAnews Drug Daily Bulletin
Oct. 23, 2012 | Vol. 9 No. 208
ANDA Filers Fret: Stability Testing Tweaks Will Delay Approvals
The FDA’s plan to require more stability data for ANDAs is likely to slow approvals unless the agency flexes a little, generic-drug makers say. The FDA should consider three months of stability data instead of six months — at least during initial filing of an ANDA, Jubilant Life Sciences said in initial comments on draft agency guidance. The full six-month data set could be provided later in the review process.
Drug Industry Daily
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.